A RANDOMISED TRIAL OF DENTRIC CELL VACCINATION WITH NY-ESO-1 AND ALPHA- GALACTOSYLCERAMIDE IN PATIENTS WITH METASTATIC MELANOMA (ACTRN12612001101875)

被引：0
|
作者：
Dasyam, N. [1 ]
Sharples, K. [2 ]
Barrow, C. [3 ]
Bauer, E. [1 ]
Mester, B. [1 ]
McCusker, M. [4 ]
Painter, G. [5 ]
Weinkove, R. [3 ]
Brimble, M. [6 ]
Dunbar, R. [6 ]
Gasser, O. [1 ]
Hermans, I. [1 ]
机构：
[1] Malaghan Inst Med Res, Wellington, New Zealand
[2] Univ Otago, Dunedin Sch Med, Dunedin, New Zealand
[3] Wellington Reg Hosp, Capital Coast Dist Hlth Board, Wellington, New Zealand
[4] Univ Auckland, Canc Trials New Zealand, Auckland, New Zealand
[5] Victoria Univ Wellington, Ferrier Res Inst, Wellington, New Zealand
[6] Maurice Wilkins Ctr Mol Biodiscovery, Auckland, New Zealand
来源：
CYTOTHERAPY | 2021年 / 23卷 / 05期
关键词：
Vaccine;
D O I：
暂无
中图分类号：
Q813 [细胞工程];
学科分类号：
摘要：
427
引用
收藏
页码：S98 / S98
页数：1
相关论文
共 44 条
  • [21] Poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 VG in patients with melanoma.
    Sabado, Rachel Lubong
    Pavlick, Anna C.
    Gnjatic, Sacha
    Hasan, Farah
    Spadaccia, Meredith
    Oner, Bike Su
    Dong, Hanqing
    Holman, Rose Marie
    Vengco, Isabelita
    Muren, Caroline
    Escano, Crystal
    Yepes, Ethel
    Stein, Claire
    Jungbluth, Achim A.
    Pan, Linda S.
    Venhaus, Ralph Rudolph
    Salazar, Andres M.
    Ott, Patrick Alexander
    Bhardwaj, Nina
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [22] Lack of XAGE-1b and NY-ESO-1 in metastatic lymph nodes may predict the potential survival of stage III melanoma patients
    Mori, Mariko
    Funakoshi, Takeru
    Kameyama, Kaori
    Kawakami, Yutaka
    Sato, Eiichi
    Nakayama, Eiichi
    Amagai, Masayuki
    Tanese, Keiji
    JOURNAL OF DERMATOLOGY, 2017, 44 (06): : 671 - 680
  • [23] Immunization of HLA-A*0201 and/or HLA-DPβ1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen
    Khong, HT
    Yang, JC
    Topalian, SL
    Sherry, RM
    Mavroukakis, SA
    White, DE
    Rosenberg, SA
    JOURNAL OF IMMUNOTHERAPY, 2004, 27 (06) : 472 - 477
  • [24] Randomized phase I-II study of vaccination with CpG 7909, Montanide ISA 720 and NY-ESO-1 peptides for patients with stage III/IV melanoma and NY-ESO-1+ tumors: An interim analysis
    Zarour, HM
    Andrade, P
    Mandic, M
    Kudela, P
    Janjic, B
    Land, S
    Stover, L
    Shipe-Spotloe, J
    Argawala, S
    Krieg, A
    Kirkwood, J
    JOURNAL OF IMMUNOTHERAPY, 2005, 28 (06) : 661 - 662
  • [25] Tumor-reactive CD8+ T-cell clones in patients after NY-ESO-1 peptide vaccination
    Karbach, Julia
    Gnjatic, Sacha
    Pauligk, Claudia
    Bender, Armin
    Maeurer, Markus
    Schultze, Joachim L.
    Nadler, Kerstin
    Wahle, Claudia
    Knuth, Alexander
    Old, Lloyd J.
    Jaeger, Elke
    INTERNATIONAL JOURNAL OF CANCER, 2007, 121 (09) : 2042 - 2048
  • [26] Cytotoxic T Lymphocyte-associated Antigen 4 Blockade Enhances Polyfunctional NY-ESO-1 Specific T Cell Responses in Metastatic Melanoma Patients With Tumor Regression
    Yuan, Jianda
    Gnjatic, Sacha
    Li, Hao
    Powel, Sarah
    Gallardo, Humilidad
    Ritter, Erika
    Rasalan, Teresa S.
    Manukian, Gregor
    Xu, Yinyan
    Terzulli, Stephanie
    Ritter, Gerd
    Old, Lloyd
    Allison, James P.
    Wolchok, Jedd D.
    JOURNAL OF IMMUNOTHERAPY, 2008, 31 (09) : 934 - 935
  • [27] Regulatory T-Cell - Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma
    Nicholaou, Theo
    Ebert, Lisa M.
    Davis, Ian D.
    McArthur, Grant A.
    Jackson, Heather
    Dimopoulos, Nektaria
    Tan, Bee
    Maraskovsky, Eugene
    Miloradovic, Lena
    Hopkins, Wendie
    Pan, Linda
    Venhaus, Ralph
    Hoffman, Eric W.
    Chen, Weisan
    Cebon, Jonathan
    CLINICAL CANCER RESEARCH, 2009, 15 (06) : 2166 - 2173
  • [28] NY-ESO-1 Vaccination in Combination with Decitabine for Patients with MDS Induces CD4+and CD8+T-Cell Responses
    Srivastava, Pragya
    Matsuzaki, Junko
    Paluch, Benjamin E.
    Brumberger, Zachary
    Kaufman, Stephanie
    Karpf, Adam R.
    Odunsi, Kunle
    Miller, Austin
    Kocent, Justin
    Wang, Eunice S.
    Nemeth, Michael J.
    Griffiths, Elizabeth A.
    BLOOD, 2015, 126 (23)
  • [29] Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma
    Pavlick, Anna
    Blazquez, Ana B.
    Meseck, Marcia
    Lattanzi, Michael
    Ott, Patrick A.
    Marron, Thomas U.
    Holman, Rose Marie
    Mandeli, John
    Salazar, Andres M.
    McClain, Christopher B.
    Gimenez, Gustavo
    Balan, Sreekumar
    Gnjatic, Sacha
    Sabado, Rachel Lubong
    Bhardwaj, Nina
    CANCER IMMUNOLOGY RESEARCH, 2020, 8 (01) : 70 - 80
  • [30] A pilot trial of the combination of transgenic NY-ESO-1-reactive adoptive cellular therapy with dendritic cell vaccination with or without ipilimumab in patients with sarcoma and melanoma
    Nowicki, Theodore S.
    Berent-Maoz, Beata
    Huang, Rong Rong
    Wang, Xiaoyan
    Cheung-Lau, Gardenia
    Kaplan-Lefko, Paula
    Cabrera, Paula
    Tran, Justin
    Carretero, Ignacio Baselga
    Grasso, Catherine S.
    Hu-Lieskovan, Siwen
    Chmielowski, Bartosz
    Comin-Anduix, Begona
    Singh, Arun
    Ribas, Antoni
    CANCER RESEARCH, 2018, 78 (13)
12345